NEW YORK (GenomeWeb) – Becton Dickinson today reported a 5 percent jump in its third quarter revenues with growth across all three of its business segments.

The Franklin Lakes, NJ-based medical products, diagnostics, and research tools firm reported total revenues of $2.16 billion for the three months ended June 30, up from $2.05 billion for Q3 2013. It beat the average Wall Street estimate of $2.14 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.